Skip to main navigation Skip to search Skip to main content

A tale of two TROP-2 antibody-drug conjugates: A comparative saga of datopotamab deruxtecan and sacituzumab govitecan

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Article numberoyaf251
JournalOncologist
Volume30
Issue number9
DOIs
StatePublished - Sep 1 2025

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this